Natural compounds from herbs and nutraceuticals as glycogen synthase kinase‐3β inhibitors in Alzheimer's disease treatment

Abstract

AbstractBackgroundAlzheimer's disease (AD) pathogenesis is complex. The pathophysiology is not fully understood, and safe and effective treatments are needed. Glycogen synthase kinase 3β (GSK‐3β) mediates AD progression through several signaling pathways. Recently, several studies have found that various natural compounds from herbs and nutraceuticals can significantly improve AD symptoms.AimsThis review aims to provide a comprehensive summary of the potential neuroprotective impacts of natural compounds as inhibitors of GSK‐3β in the treatment of AD.Materials and MethodsWe conducted a systematic literature search on PubMed, ScienceDirect, Web of Science, and Google Scholar, focusing on in vitro and in vivo studies that investigated natural compounds as inhibitors of GSK‐3β in the treatment of AD.ResultsThe mechanism may be related to GSK‐3β activation inhibition to regulate amyloid beta production, tau protein hyperphosphorylation, cell apoptosis, and cellular inflammation. By reviewing recent studies on GSK‐3β inhibition in phytochemicals and AD intervention, flavonoids including oxyphylla A, quercetin, morin, icariin, linarin, genipin, and isoorientin were reported as potent GSK‐3β inhibitors for AD treatment. Polyphenols such as schisandrin B, magnolol, and dieckol have inhibitory effects on GSK‐3β in AD models, including in vivo models. Sulforaphene, ginsenoside Rd, gypenoside XVII, falcarindiol, epibrassinolides, 1,8‐Cineole, and andrographolide are promising GSK‐3β inhibitors.ConclusionsNatural compounds from herbs and nutraceuticals are potential candidates for AD treatment. They may qualify as derivatives for development as promising compounds that provide enhanced pharmacological characteristics.